Brief: Adagene Presents Clinical Data For Anti-Ctla-4 Safebody®
18/04/2023 14:19
April 18 (Reuters) - Adagene Inc 978y.F :
* ADAGENE PRESENTS CLINICAL DATA FOR ANTI-CTLA-4 SAFEBODY®
ADG126
REINFORCING BEST-IN-CLASS SAFETY PROFILE AT REPEAT DOSES AND
SHOWING EARLY EFFICACY PROFILE IN ADVANCED/METASTATIC SOLID
TUMORS
Source text for Eikon: ID:nGNX41z3hY
Further company coverage: 978y.F
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate